Sunesis Pharmaceuticals to Present at C.E. Unterberg, Towbin Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Oct 21, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today that Daniel N. Swisher, Jr., Chief Executive Officer and President, is scheduled to present a corporate update at the upcoming C.E. Unterberg, Towbin Life Sciences Conference. The presentation is scheduled for October 25, 2005 at 9 a.m. at the Palace Hotel, New York, NY.
Interested parties may access the webcast of the presentation by visiting the Sunesis website at www.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until November 8, 2005.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit www.sunesis.com.
This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.
SOURCE Sunesis Pharmaceuticals, Inc.
investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman or Michelle Corral of BCC Partners, +1-650-575-1509, or +1-415-794-8662
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX